Ipamorelin vs Hexarelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IPAM, NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Also: Examorelin, HEX
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing effect among GHRPs. Also has notable cardioprotective properties independent of GH release.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Ipamorelin | Hexarelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ipamorelin binds to ghrelin receptors (GHSR) in the pituitary gland, triggering growth hormone release. Unlike other GHRPs, it does not stimulate significant ACTH, cortisol, prolactin, or aldosterone release, making it highly selective for GH. | Hexarelin activates ghrelin receptors (GHSR-1a) causing potent GH release. Uniquely, it also binds to CD36 receptors in cardiac tissue, providing cardioprotective effects independent of GH. Causes significant cortisol and prolactin elevation. |
| Common Dosing | 200-300 mcg 2-3x daily 2-3x daily | 100-200 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks typical | 4-8 weeks (desensitization occurs) |
| Best Time to Take | Before bed or morning (fasted) | Morning and before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II trials for postoperative ileus showed good safety but failed to meet efficacy endpoints and were discontinued. Research demonstrates dose-dependent GH release with minimal side effects, improved bone density in postmenopausal women, and potential benefits for muscle mass and recovery. | Studies show the highest GH release among GHRPs but with desensitization over time. Cardiac research demonstrates protection against ischemia and improved heart function. Used in GH deficiency diagnosis due to reliable GH stimulation. |
Frequently Asked Questions: Ipamorelin vs Hexarelin
What is the difference between Ipamorelin and Hexarelin?
Ipamorelin is a growth hormone peptide that a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. considered one of the safest ghrps. Hexarelin is a growth hormone peptide that a synthetic hexapeptide gh secretagogue with the strongest gh-releasing effect among ghrps. also has notable cardioprotective properties independent of gh release. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ipamorelin or Hexarelin?
Neither is universally "better" - the choice depends on your specific goals. Ipamorelin is typically used for growth hormone purposes, while Hexarelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ipamorelin and Hexarelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ipamorelin and Hexarelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Ipamorelin and Hexarelin is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.